Klin Onkol 2021; 34(2): 137-140. DOI: 10.48095/ccko2021137.
Background: Translocation renal cell carcinoma (TRCC) is a rare form of RCC affecting mostly children and young adults with the occurrence of only 1–5% of all renal cell carcinomas. These carcinomas are associated with different translocations on a short arm of chromosome X in the region 11.2, which results in genetic modification of the p arm containing the transcription factor E3 gene. Methods: Herein we report a case of a patient who was diagnosed with TRCC with c-Met overexpression and was treated with multiple targeted therapy agents and immunotherapy. Case: A 28-year old woman without a significant past medical history underwent left sided total nephrectomy for TRCC. Seven months later, she developed systemic relapse and was treated with multiple lines of targeted therapy including sunitinib, everolimus, sorafenib, crizotinib, and pazopanib as well as with anti-PD-L1 antibody nivolumab, with stable disease as a best response. The most pronounced disease stabilization was achieved with sorafenib, which lasted 18 months. The patient died 81 months after initial diagnosis and 74 months from the diagnosis of metastatic disease. Conclusion: Improved survival observed in our patient could be related to the effectivity of tyrosine-kinase inhibitors, but not m-TOR inhibitors, even though disease stabilisation was observed as a best response. Identification of new treatment targets are warranted in this rare disease.
